The president-elect might bring back efforts to make other countries pay more for drugs, but there are pitfalls.

The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth rate (AGR) of 0.90 per cent from 2.00 million in 2023 to 2.18 million in 2033 ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD ...

RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on January 7 and set a price target of $10.00.

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ...

Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project ...

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...